{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-247434","form_type":"8-K","ticker":"BLCO","cik":"0001860742","company_name":"Bausch & Lomb Corp","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.855262+00:00","generated_at":"2026-06-10T07:06:07.201661+00:00","sec_items":["1.01","2.01","9.01","2.03"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bausch + Lomb completes $2.5B acquisition of XIIDRA from Novartis, funded by $1.4B notes and $500M term loans","bullets":["Acquired XIIDRA, libvatrep (Phase 2b), and AcuStream tech from Novartis for up to $2.5B ($1.75B upfront + $750M milestones).","Funded with $1.4B of 8.375% senior secured notes due 2028 and $500M incremental term B loans.","XIIDRA adds non-steroid dry eye treatment; combined with MIEBO, targets leading position in growing prescription DED market.","Libvatrep Phase 2b study results expected H2 2023; AcuStream device aims at precise ophthalmic dosing.","CEO Brent Saunders expects to 'quickly take a leading position in the growing prescription dry eye category.'"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-247434","json":"https://secwatch.observer/filing/0001193125-23-247434.json","markdown":"https://secwatch.observer/filing/0001193125-23-247434.md","text":"https://secwatch.observer/filing/0001193125-23-247434.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860742/000119312523247434/0001193125-23-247434-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860742/000119312523247434/d655401d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:06:07.201661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc41a3be96f7374dbe969e53f894f24354253bb4","claim":"Bausch & Lomb Corp completed an acquisition involving Novartis Pharma AG, Novartis Finance Corporation (closed 2023-09-29).","evidence_excerpt":"On September 29, 2023, the Company completed the Acquisition pursuant to the terms and conditions of the previously announced Stock and Asset Purchase Agreement","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860742/000119312523247434/0001193125-23-247434-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Novartis Pharma AG, Novartis Finance Corporation"},{"label":"Closing","value":"2023-09-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}